National Health (February 2025 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2024

Overview

The National Health (February 2025 First New Brand Statutory Price Reduction) (Exercise of Ministerial Discretion) Determination 2024, also known as PB 147 of 2024, was enacted in 2024 to address the need for specific statutory price reductions for certain pharmaceutical brands within the National Health Act 1953. This determination is made under subsection 99ACB(6A) of the Act by Eden Simon, the Acting Assistant Secretary of the Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, as a delegate of the Minister for Health and Aged Care. The primary objective of this legislation is to exercise the Minister's discretion in determining a lower percentage reduction for the maximum agreed price of specified pharmaceutical items, which in this case is a 10% reduction for the brand of pharmaceutical item nab-PACLITAXEL JUNO. This legislative instrument is designed to ensure that the pricing of certain new pharmaceutical brands aligns with broader health policy objectives, potentially enhancing affordability and access to essential medications. By implementing this determination, the Act aims to provide a more equitable pricing structure for specific pharmaceutical items, thereby addressing any discrepancies that might otherwise exist under the general statutory price reduction mechanisms. The determination will come into force on 1 February 2025, as stipulated in the instrument.

Scope and Application

The National Health (February 2025 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2024 applies to the pricing of specific pharmaceutical brands listed in the Schedule, specifically affecting the maximum agreed price of the brand of pharmaceutical item, nab-PACLITAXEL JUNO, which is a powder for intravenous injection containing 100 mg paclitaxel. This determination is made under the authority granted by the National Health Act 1953 and applies to the Commonwealth of Australia. The determination specifically reduces the maximum agreed price of the listed pharmaceutical item by 10% from what would otherwise apply, effective from 1 February 2025. The scope of this Act extends to the entities and industries involved in the manufacture and sale of the specified pharmaceutical item, impacting their pricing strategies and potentially their profitability. This determination is a clear exercise of ministerial discretion aimed at influencing the pricing dynamics within the national healthcare system.

Key Provisions

The main operative sections of this Determination (sections 1-5) outline its name, commencement date, definitions, authority, and the specific determination regarding the pharmaceutical item's price reduction. Section 1 names the instrument and its alternative citation, while section 2 specifies that it will commence on 1 February 2025. Section 3 notes that several terms are defined in Part VII of the Act, and section 4 confirms that the instrument is made under subsection 99ACB(6A) of the National Health Act 1953. Section 5 is the core of the Determination, stipulating that the maximum agreed price of the specified brand of pharmaceutical item will be calculated using a reduction of 10%, as per subsection 99ACB(6A) of the Act. The obligations and requirements imposed by the Act and this Determination primarily concern the calculation and application of the statutory price reduction for the specified brand of pharmaceutical item. The Minister, through the Acting Assistant Secretary, is required to determine the maximum agreed price using a lower percentage reduction than would otherwise apply. This requirement ensures that the pricing of the specified pharmaceutical item is in line with the policy objectives set out in the Act, particularly those relating to the affordability and accessibility of pharmaceutical items. The Determination also outlines the consequences for non-compliance with the statutory provisions. While specific offences and penalties are not detailed in the text, breaches of the National Health Act 1953 and its associated instruments can lead to civil or criminal penalties, depending on the nature and severity of the breach. The Act provides for fines and, in some cases, imprisonment for serious or repeated violations. For the purposes of this Determination, non-compliance with the specified price reduction could result in financial penalties or other enforcement actions taken by the relevant authorities to ensure adherence to the legislative requirements.